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Selective internal radiation therapy has emerged as a well-accepted therapeutic for primary and
metastatic hepatic malignancies. This therapeutic modality requires the combined efforts of
multiple medical disciplines to ensure the safe delivery of yttrium-90 (90Y)-labeled microspheres.
The development of this therapy followed decades of clinical research involving tumor vascularity
and microsphere development. Today, it is essential that treating physicians have a thorough
understanding of hepatic tumor vascularity and 90Y microsphere characteristics before
undertaking this complex intervention. This review explores the contributions of early
investigators of this therapy, as well as the development, US Food and Drug Administration
approval, manufacturing process, and attributes of the 2 commercially available 90Y
radiolabeled microsphere device to clarify the key physical differences between the products.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/primary and metastatic hepatic malignancies. During
SIRT, millions of yttrium-90 (90Y)-radiolabeled micro-
spheres are injected into the hepatic arteries preferentially
depositing into tumors because of their increased vascu-
larity, with the goal of delivering lethal doses of radiation
to tumors but sublethal doses to normal parenchyma. The
treatment algorithm for this therapy is complex and in-
volves many different health care professionals with
different areas of expertise including interventional radi-
ologists, nuclear medicine physicians, radiation oncolo-
gists and physicists, and medical and surgical oncologists.
A thorough understanding of the available products usedof the American Society for Radiation Oncology. This is an open access
by-nc-nd/4.0/).
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ment team to ensure successful outcomes and to limit
treatment-related complications. Many treating physicians
favor the use of 1 of the 2 commercially available 90Y
microsphere products based on their fellowship training
or the preferences at their institution and may be unfa-
miliar with the key characteristics of the alternative
microsphere device. The following review will explore
the contributions of early investigators of this therapy, the
development, US Food and Drug Administration (FDA)
approval, manufacturing process and attributes of the
2 commercially available 90Y-radiolabeled microsphere
devices, and the potentially clinically relevant differences
based on the products’ physical properties.
Yttrium discovery and physical properties
In 1787, Carl Arrhenius discovered a mineral not
previously identiﬁed in a mine near Ytterby, Sweden, and
named it ytterbite. Analyses by Gadolin et al and Ekeberg
et al found that the mineral was composed of several
different elements including a previously unknown metal,
which was subsequently named yttrium.1 90Y is produced
for labeling of microspheres by the neutron bombardment
of stable yttrium 89 but can also be developed by
chemical separation from its parent isotope strontium 90.2
The decay of 90Y is primarily through b() emission of a
high-speed electron to stable zirconium-90 with an
average energy of 0.9367 MeV, a mean tissue penetration
of 2.5 mm and a maximum of 11 mm, and a half-life of
2.67 days (64.2 hours). A small portion of decay, how-
ever, is through pair production, which has recently been
used to assess 90Y microsphere distribution after SIRT
with positron emission tomography (PET) imaging.2,3
During deceleration of the high-energy electrons in the
atomic electric ﬁeld, continuous X-rays or bremsstrahlung
(“braking” gamma radiation) are produced. Imaging of
this bremsstrahlung radiation is currently the most com-
mon manner in which distribution of microspheres are
determined following SIRT.4
Radioembolization: Early experience and
development
1950s to 1960s
Beginning in the early 1950s and continuing through
the 1980s, investigators discovered the key elements of
hepatic tumor vascularity, which allowed for the devel-
opment of hepatic arteryedirected therapies. In 1951,
Bierman et al demonstrated angiographically that liver
tumors received their blood supply from the hepatic artery
and not the portal vein.5 This was conﬁrmed by Breedis
and Young in 1954.6 Further study led to the conclusionthat hepatic malignancies received greater than 80% of
their blood supply from the hepatic artery while the
normal liver parenchyma received less than one-third.7
These early studies allowed for future investigators to
postulate that hepatic arterial-directed therapies may be an
effective means of treating hepatic malignancies.
In the 1960s, there were concurrently several reports of
hepatic radioembolization with 90Y. Early animal studies
by Grady et al demonstrated the feasibility of treating
tumors with 90Y and paved the way for human applica-
tions.8 Simon et al reported on 5 patients with hepatic
neuroendocrine tumors and carcinoid syndrome who were
treated with hepatic artery radioembolization using
carbonized microspheres 15 microns in diameter
embedded with 90Y. The authors discussed the key issues
of the technical aspects of the therapy that are still rele-
vant today including intratumoral lung shunts, selective
catheterization, dosimetry, preferential deposition of
microspheres in tumors, bremsstrahlung scans to evaluate
radiation distribution and, most important, nontarget
delivery. Unfortunately, 2 of the patients in the cohort
developed signiﬁcant gastric symptoms from uninten-
tional irradiation of the stomach, which is not surprising
given the unsophisticated catheters and angiographic
techniques available at the time.9 Other reports described
the use of 90Y in the treatment of lung cancers, osteogenic
sarcomas, and other tumors using plastic and ceramic
microspheres with different techniques and, unfortu-
nately, overall poor results.10,111970s to 1980s
The following decade brought further advances in the
understanding of hepatic and tumor vascularity, which led
the way for the development of techniques to treat liver
tumors more effectively through the hepatic artery.
Ackerman studied rat tumors and determined that, after
tumors reached a diameter of 3 mm, they had developed
an arterial supply.12 Taylor et al showed that colorectal
metastases received most of their blood supply from the
hepatic artery but when it was ligated, portal vein supply
to tumors signiﬁcantly increased, demonstrating what we
now know to be the arterial portal communications that
exist at the sinusoidal level.13 After colleagues attempted
radioembolization through the portal vein with little suc-
cess, Grady used a 15-micron resin 90Y microsphere
injected intra-arterially and reported on 25 patients with
metastatic colon cancer, 17 of whom had an “objective
decrease” in tumor size. He suggested that those tumors
with greater vascularity on angiography should respond
more favorably to the treatment.14
In 1983, Stribley et al reported that after injecting
15 micron Cobalt-57 labeled microspheres into the he-
patic arteries of rats with implanted salivary adenocarci-
noma, the periphery of the tumor consistently
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liver parenchyma with a progressive decrease in blood
ﬂow toward the central part of tumors once a tumor
diameter of 6 mm had been exceeded.15 This supports the
premise that microsphere distribution during radio-
embolization is concentrated in the periphery of many
tumors. In 1987, Meade et al evaluated the distribution of
different-sized microspheres in experimental rat liver
tumors and normal hepatic parenchyma and demonstrated
that 15- and 32.5-micron diameter particles lodged pref-
erentially in tumors versus normal parenchyma with a
ratio of 3:1. Microspheres of 50 microns in diameter
showed no preferential distribution into tumors with equal
distribution demonstrated between normal parenchyma
and tumors.16
This impacted future decisions regarding microsphere
design. Mantravadi et al later noted that increased
vascularity, absence of extrahepatic disease, and good
performance status were determinants of a successful
outcome following SIRT,17 concepts that have been
demonstrated in numerous studies and are widely
accepted today.18-21
Toxicities related to radioembolization were reported
in early studies, including elevation of liver enzymes,
radiation pneumonitis, radiation hepatitis (renamed
radiation-induced liver disease and recently radio-
embolization induced liver disease) and gastrointestinal
ulceration.14,22-24 Additionally, some patients in these
early trials developed myelosuppression, leading to death
secondary to leaching of yttrium from the microspheres
and subsequent deposition in bone marrow.17 This
leaching phenomenon led to decreased interest in SIRT
and eventual discontinuation of existing microsphere
manufacturing. Development of yttrium-binding tech-
niques that would eliminate or signiﬁcantly reduce
leaching became a primary focus of advanced micro-
sphere technology for both glass and resin platforms in
the late 1980s and early 1990s.Late 1980s to 1990s
In the late 1980s and 1990s, preclinical dosimetry
considerations and phase 1 trials emerged regarding both
resin and glass microspheres. Burton and Gray and their
colleagues at the University of Western Australia obtained
tissue samples after resin 90Y administration showed a
mean absorbed dose of tumor to liver of 6:1 (range,
0.4-45:1) and suggested that intra-arterial injection of
angiotensin II would allow for greater ﬂow to tumors
because of its selective vasoconstrictive activity on
normal hepatic microvasculature.25 An animal study in
1988 on the recently developed glass microsphere,
TheraSphere (BTG International Group),26 was followed
by an early human study by Herba, who reported on the
treatment of 15 predominantly metastatic colorectalcancer (mCRC) patients, with 10 patients showing stable
disease at 7 months after TheraSphere treatment and 5
showing progression. This was one of the ﬁrst articles to
discuss coil embolization of hepatic arteries to allow for
redistribution and injection of technetium 99-labeled
macroaggregated albumin to determine lung shunt and
extrahepatic supply before radioembolization.27
Three years later, Anderson studied different sized
microspheres (12.5, 25, and 40 microns) and their relative
distribution between liver tumors and normal liver in a rat
model similar to the study conducted by Meade described
earlier.16,28 He concluded that optimal ratios were ach-
ieved with the larger 40 micron particles over smaller
particles. Tumor to normal liver distribution ratios for the
three sized microspheres were 0.5, 1.4, and 1.8, important
information, which further impacted microsphere
design.28FDA approval of resin microspheres
In the 1990s, Gray and his colleagues studied a resin
microsphere labeled with 90Y and developed a technique
for its administration, which they named SIRT. Following
a laparotomy, a catheter was placed into the hepatic
arteries, redistribution of blood performed using a vaso-
active agent (angiotensin II) that caused vasoconstriction
of normal hepatic parenchymal vessels but not tumor
vessels, and the radiolabeled microspheres were then
injected to a desired liver dose measured intraoperatively
using a survey meter. In 1989, they reported on the ﬁrst
10 patients with mCRC treated with SIRT, escalating the
dose of radiation to the normal liver. Assuming a homo-
geneous distribution of microspheres, those patients who
received greater than 30 Gy to the normal liver had a
decrease in carcinoembryonic antigen (CEA) level greater
than 50%.29 In 1992, the group reported on an additional
29 patients with all evaluable patients demonstrating a
decrease in the CEA level at 3 months (mean 70%
decrease).30 Based on these data, Gray and colleagues
modiﬁed their technique, which allowed for attaching the
hepatic arterial catheter to a subcutaneous port so patients
could receive intra-arterial infusion of chemotherapy
subsequent to SIRT. Following a retrospective analysis of
71 mCRC patients treated with SIRT and ﬂoxuridine
administered through the arterial infusion catheter in
2000, which reported an 89% response rate of CEA,31
Gray and colleagues published the results of a random-
ized controlled trial involving 70 patients with mCRC.
In this pivotal trial, patients who received a single session
of 90Y-labeled resin microspheres plus monthly
hepatic artery infusions of ﬂoxuridine showed a
signiﬁcantly increased objective tumor response (50% vs
24% [P Z 0.03]) and improved median time to pro-
gression in the liver (12 vs 7.6 months [PZ 0.04]) when
compared with patients receiving only hepatic artery
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these studies, the FDA granted premarket approval (PMA;
the FDA process of scientiﬁc and regulatory review to
evaluate the safety and effectiveness of class III medical
devices. PMA approval is based on a determination by
FDA that the PMA contains sufﬁcient valid scientiﬁc
evidence to assure that the device is safe and effective for
its intended use(s)33 for SIR-Spheres in 2002 with an
approved indication for the treatment of unresectable
metastatic liver tumors from primary colorectal cancer
with adjuvant intrahepatic artery chemotherapy of
FUDR.34 SIR-Spheres microspheres are manufactured
and distributed by Sirtex Medical Ltd. (North Sydney,
Australia).
Humanitarian device exemption for glass
microspheres
Following the development of the 90Y glass micro-
sphere, TheraSphere, through collaboration between the
University of Missouri and Theragenics Corporation
(Atlanta, Georgia) in the early 1980s, several animal
studies were conducted including a canine trial performed
by Wollner and colleagues at the University of Michigan
in 1988. Doses 12 times those anticipated for humans
were administered, which were well-tolerated with mini-
mal hepatic injury. Although observed damage increased
with increasing dose, radiation exposure greater than 300
Gy did not cause total hepatic necrosis and the animals
survived.26
A pilot trial for the use of glass microspheres in
hepatocellular carcinoma (HCC)35 and 2 mixed neoplasia
studies27,36 evaluated more than 100 patients who
received TheraSphere; the data from these trials supported
the manufacturer’s safety claims. These 3 trials led to the
approval of TheraSphere in Canada in 1991 for the
treatment of liver neoplasia.37
A fourth phase 2 trial, which enrolled 22 patients with
HCC who were treated with glass microspheres with a
planned dose of 100 Gy to the liver, was then conducted.
Of the 22 enrolled, 20 patients were evaluated for thera-
peutic efﬁcacy. The median survival was 378 days from
the time of treatment with a 20% response rate.38 Based
on the ﬁnding of this study, the FDA concluded that there
was a probable beneﬁt of 90Y glass microspheres for the
treatment of HCC. In 1999, the FDA cited these 4 trials as
the evidence leading to their granting of a humanitarian
device exemption (HDE) for TheraSphere for use in
patients with unresectable HCC.37 The FDA deﬁnes a
human use device as one that is intended to beneﬁt
patients with any disease or condition that affects fewer
than 4,000 individuals per year in the United States. An
HDE, which in distinction to a PMA, does not require
effectiveness data. Applicants of an HDE must demon-
strate that the device does not “pose unreasonable orsigniﬁcant risk of illness or injury” and that the probable
beneﬁt of the device “outweighs the risk of injury or
illness from the disease.” Institutional review board
review and approval must be performed before the use of
a human use device at a facility and ongoing review of its
use performed at regular intervals.39 Currently, Thera-
Sphere is manufactured by Nordion (Ottawa, Ontario
Canada) and distributed by BTG International Group
(London, United Kingdom).
Microsphere production and physical
characteristics
SIR-Spheres
SIR-Spheres (Sirtex Medical) are composed of a pro-
prietary biocompatible microsphere, coated with a
partially cross-linked cation exchange polystyrene resin
(Bio-Rad, Hercules, CA). 90Y is incorporated into the
resin matrix (no nonintended radioactive impurities)
through ion exchange of sodium for yttrium and at this
point in the process is attached but not yet immobilized to
the microspheres. 90Y is then immobilized to the micro-
sphere following its precipitation as a phosphate salt.40,41
Despite its immobilization, the manufacturer does not
recommend exposing the microspheres to ionic solutions
(ionic contrast, saline).42 The initial patent application for
the resin microspheres indicated that 0.01% to 0.4%
of 90Y is released from the microsphere after 20 minutes
in water.41 The remainder is permanently bound to the
resin microspheres and does not leach under physiological
conditions.43 The speciﬁc gravity of resin microspheres is
1.6 g/dL (glass, 3.7 g/dL; blood, 1.05 g/dL), with a mean
diameter of 32 mm.44,45
Before April 2013, SIR-Spheres were manufactured
for Sirtex by the Australian Radiologic Institute. Each
batch produced included a set mass of resin, which yiel-
ded between 5 and 14 vials of microspheres containing 3
GBq of activity depending on the number of submitted
orders. The batches producing 5 vials contained approx-
imately 80 million spheres per vial (speciﬁc activity, 37.5
Bq/sphere; mean diameter, 25 mm) and those producing
14 vials contained approximately 40 million spheres per
vial (speciﬁc activity, 75 Bq/sphere). There are currently
three manufacturing sites all of which are owned by Sirtex
Medical (Wilmington, MA; Singapore; Frankfurt).46
Production processes were changed such that each vial,
regardless of the batch size, contains the same mass of
resin resulting in approximately 40 million microspheres
per vial (speciﬁc activity, 75 Bq/sphere) (G. Spindler,
verbal communication, October 2016). An activity
administration of 1 GBq, therefore, will consistently
deliver approximately 13 million microspheres at the time
of calibration. 90Y radiolabeled resin microspheres are
ordered the week before administration and are delivered
Table 1 Estimated activities for TheraSphere vials dispensed Monday and calibrated the Sunday prior
Available
activities
(GBq)
Microspheres
(millions)
Activity at time of administration (GBq)
Monday Tuesday Wednesday Thursday Friday Monday Tuesday Wednesday Thursday
3 1.2 2.7 2.1 1.6 1.2 0.95 0.43 0.3 0.2 0.17
5 2 4.5 3.5 2.7 2.1 1.6 0.7 0.5 0.4 0.29
7 2.8 6.3 4.8 3.7 2.9 2.2 1 0.7 0.5 0.40
10 4 9.0 6.9 5.3 4.1 3.2 1.5 1.0 0.76 0.57
15 6 13.5 10.4 8.0 6.2 4.8 2.2 1.5 1.1 0.86
20 8 18 13.8 10.7 8.2 6.3 2.9 2.0 1.5 1.15
A 1 GBq administration may represent between 1.2 million and 7 million microspheres depending on date of delivery. A Thursday administration
would require a 3 GBq vial, or an extended shelf-life administration on the following Thursday would require 17.5 GBq.
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Mondays through Fridays as same- or next-day treat-
ments. The vial of microspheres is calibrated to be 3 GBq
 10% at 6 PM the day following delivery to the insti-
tution and can be used up to 24 hours after
calibration.42,47TheraSphere
The manufacturing process of TheraSphere involves
mixing yttrium-89 (89Y) with ultrapure aluminum
oxide and silicone dioxide, which is then melted in a
furnace at 1500C. After cooling, the 89Y embedded
glass is crushed and passed through a ﬂame sprayer,
causing the glass particles to melt and “spheridize.”
The spheres are ﬁltered through sieves to select for
those with a diameter of 20 to 30 microns. Neutron
bombardment of the spheres then converts the
embedded 89Y to 90Y. Because 90Y is embedded in the
glass matrix, the possibility of leaching from the mi-
crospheres is minimal.48 Although 90Y dominates in
the glass matrix, there are unintended radioactive
substances present with long half-lives because of
neutron bombardment of aluminum and silicone (88Y
half-life 107 days, 154Europium half-life 8 years). The
density of the glass microspheres is 3.6 g/dL, which is
approximately 3 times that of blood (1.05 g/dL). The
speciﬁc activity of the glass microsphere is approxi-
mately 2500 Bq per sphere at the time of calibration.44
There are 6 activity sizes available for delivery: 3, 5, 7,
10, 15, and 20 GBq. A 3-GBq vial contains approxi-
mately 1.2 million microspheres and a 20-GBq vial
approximately 8 million. TheraSphere is supplied in
0.6 mL of sterile water in a 1.0-mL vial.49 They are
dispensed Mondays, Wednesdays, and Thursdays and
are calibrated for 12:00 PM (EST) the prior Sunday
(vials dispensed Monday) or the following Sunday
(vials dispensed Wednesday and Thursday). Activities
over time for the different available vials are given in
the following chart (Table 1).Note that there is an option to perform radio-
embolization the week following delivery of glass mi-
crospheres to an institution, allowing for use up to 12
days following calibration (EX or extended shelf life).
This method allows for the administration of more mi-
crospheres with a lower speciﬁc activity as the number of
half-lives increases, with a potential added beneﬁt of
improved tumor coverage. With the use of the EX pro-
tocol, the speciﬁc activity may be reduced to as low as
150 Bq/sphere. Lewandowski et al treated 134 patients
with extended shelf-life glass microspheres resulting in
the delivery of approximately twice as many spheres as
would have been delivered with a standard protocol. The
occurrence of clinical toxicities were similar to previous
cohorts using standard administration techniques with
response rates reported at 48% (World Health Organiza-
tion) and 57% (European Association for the Study of
Liver) and a complete European Association for the Study
of Liver response of 21%. The authors concluded that
“the increase in number of microspheres administered
theoretically resulted in better tumor distribution of the
microspheres without an increase in adverse events.”50
Microsphere production and physical
characteristics: Advantages and
disadvantages
There are advantages and disadvantages of the 2 de-
vices related to their physical characteristics and the
manner in which they are supplied that have important
clinical implications.
For the glass device, the sealed vial cannot be altered
in any way and must be administered at a speciﬁc time
during its decay based on the calculated activity for each
patient. Although this does reduce radiation exposure to
nuclear medicine staff and simpliﬁes the steps involved in
its administration, the inability to make changes to the
treatment plan can be limiting. The ability to fractionate
the activity of the delivered resin device allows for greater
ﬂexibility in timing of administration and changes to the
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exposure to the nuclear medicine staff.
Because the speciﬁc gravity of resin microspheres is
close to that of blood they are more uniformly distributed
within the blood stream and therefore potentially more
uniformly distributed throughout the tumor vascular bed
than the more than twice as heavy glass microspheres.44
Ibrahim showed, however, that there was no actual
difference in tumor response between the anterior and
posterior segments after administration of glass micro-
spheres and concluded that the speciﬁc gravity of glass
microspheres does not appear to impede their tumor dis-
tribution.51 Recently, Jernigan developed a surrogate he-
patic arterial system, which included a tumor and injected
glass and resin microspheres. He determined that the
penetration depths of microspheres into the tumor, which
are dependent on ﬂuid drag, gravity, and pressure forces,
were signiﬁcantly greater for resin microsphere due to
their larger size and lower speciﬁc gravity than for the
small glass microspheres with higher speciﬁc gravity.52
Basciano, also using a ﬂow model, determined that if
microspheres were injected at velocities greater than the
native arterial velocity, they would be diverted from the
normal ﬂow patterns in the low-resistance tumor vessels
into higher resistance vessels not supplying tumors.53
Because of their higher speciﬁc gravity, glass micro-
spheres must be injected more forcefully, which may lead
to microspheres achieving velocities rates greater than the
native artery velocity and subsequent suboptimal distri-
bution into liver tumors.
One of the most contentious issues related to resin
microspheres concerns ﬂow reductions and stasis seen
during some administration. This observation has led to
the presumption that, because of their lower speciﬁc ac-
tivity and therefore larger required number of spheres
delivered during a treatment, the spheres have an embolic
effect limiting the complete administration of the desired
activity. Piana et al reported an overall incidence of stasis
of 20% with the use of sterile water during SIR-Spheres
administrations, with a 36.6% incidence seen during left
lobe administrations, 15.4% during right lobe infusions,
and only 4.5% of whole liver infusions.54 Despite these
observations, an analysis of 680 SIR-Spheres adminis-
trations using sterile water showed that the median
administered activity was approximately 92% of the
drawn activity (prescribed: 1.2  0.06 GBq; adminis-
tered: 1.1  0.06 GBq).55
Bilbao injected cold SIR-Spheres microspheres into
the left lobe of pigs to stasis using sterile water and saw
no microscopic evidence of vascular occlusion, ischemia,
or infarction.56 Additionally, with the new production
process resulting in fewer than 40 million resin micro-
spheres per vial and the ability to deliver fewer spheres
with higher speciﬁc activity the day before calibration, the
number of spheres delivered for a given prescribed ac-
tivity has decreased and is similar to the number ofspheres administered during a TheraSphere EX treatment
when the lower overall activity administered using the
standardized body surface area (BSA) method is
implemented.
The diluent initially used for the administration of SIR-
Spheres was sterile water, chosen by the manufacturer as
an extra safety precaution because it is nonionic. It is
known that intravascular injection of sterile water,
because of its hypotonicity relative to blood, causes
vascular disturbances, which can lead to spasm and
thrombosis.57,58 Sterile water rapidly enters red blood
cells with subsequent lysis and release of free hemoglo-
bin. When the capacity of protective hemoglobin scav-
enging mechanisms has been saturated, levels of cell-free
hemoglobin increases in plasma and reacts with nitric
oxide, converting it to biologically inactive nitrate. Nitric
oxide plays a major role in vascular homeostasis and has
been shown to be a regulator of smooth muscle relaxation
(maintaining vasodilatation) and vasomotor tone, platelet
activation and aggregation, and thrombin generation. The
end result of nitric oxide consumption is acute vasocon-
striction and chronic proliferative vasculopathy.58,59
Additionally, water also causes lysis of endothelial
cells, which can expose basement membrane leading to
platelet aggregation, and activation of the clotting cascade
as well as initiating repair mechanisms, which subse-
quently lead to intimal hyperplasia and arterial
narrowing.58
Because of the profound physiologic effect of sterile
water on the vasculature, it was felt by many early cli-
nicians performing SIRT with SIR-Spheres that water was
the cause of changes in ﬂow seen during resin micro-
sphere administration because these changes were seen
even after a few aliquots of microspheres.
Sirtex evaluated different diluents and determined that
5% dextrose in water (D5W) combined with nonionic
contrast was compatible with SIR-Spheres and was
therefore an acceptable alternative to sterile water. D5W
is isotonic to plasma and is not associated with hemolysis,
signiﬁcant ﬂow reductions, or stasis as seen with the use
of sterile water. Its use during the administration of SIR-
Spheres was approved by the FDA in October 2014.60
Ahmadzadehfar retrospectively evaluated 104 SIRT pro-
cedures in 78 patients using SIR-Spheres at the time of the
switch from sterile water to D5W as the diluent (50 sterile
water, 54 D5W). They found that the whole prescribed
activity was administered in signiﬁcantly more procedures
with D5W than with sterile water (85% vs 22%), a sta-
tistically signiﬁcant higher percentage of activity admin-
istered in the D5W group (96% vs 77.4%) and a
statistically signiﬁcant lower incidence of stasis (11% vs
28%). In addition, there was a signiﬁcantly lower inci-
dence of intraprocedural pain in the D5W group (1.8% vs
44%).61
There have been no clinical trials demonstrating su-
periority or inferiority of glass or resin microspheres in
Figure 1 Calculated activity and number of resin/glass microspheres that would be prescribed for a patient with liver dominant
metastatic colon cancer who is 5’10” tall, weighs 170 pounds, and has a right lobe tumor (275 cc) with 3% lung shunt.
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embolization. Administration of resin microspheres is
performed with real-time evaluation of blood ﬂow,
which is not possible with the current administration
technique for glass microspheres. Sato et al, however,
did report that the angiographic patency rate was 100%
following the administration of glass microspheres in 30
patients.62 When reductions in blood ﬂow are perceived
during resin administration, they may improve after a
short time (5 to 10 minutes). One explanation for this
phenomenon is that the microspheres might initially
aggregate in larger vessels, decreasing ﬂow, but then
over time distribute into smaller vessels leading to
resumption of normal ﬂow in the territory. Users of both
products may choose 1 product over the other in certain
patients because of concerns about the possibility of
blood ﬂow changes. A special situation involves the
attempt to perform so-called “radiation segmentectomy”
wherein a very large activity is delivered to a segment to
destroy all tumor and normal hepatic parenchyma. If the
region targeted is a small volume, then it is possiblypreferable to delivery fewer microspheres with the
highest speciﬁc activity (non-EX glass microspheres or
resin microspheres administered on day of delivery to
institution); however, this has not been supported by the
literature to date.
Antireﬂux catheters are currently available and may
impact particle distribution. At the present time, their role
in radioembolization has yet to be determined.Activity calculation and delivery
The methods involved in calculating activity to be
administered and delivery of microspheres differ signiﬁ-
cantly between the glass and resin products. Calculated
activities for glass are always higher than resin, but cannot
be directly compared because of differences in speciﬁc
activity between the 2 products. Fewer glass spheres with
higher speciﬁc activity are required to achieve a desired
administered activity; however, this results in decreased
tumor coverage (Fig 1).
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internal radiation dose, macrodosimetry is the most ac-
curate means to determine the dose administered to the
liver tumor, the normal parenchyma, and the lung63;
however, it is rarely used in clinical practice because of its
complexity and difﬁculty in obtaining accurate tumor to
normal uptake ratio following technetium 99-labeled
macroaggregated albumin injections during mapping
arteriograms. The tumor to normal uptake ratio is unre-
liable, inconsistent, and varies between tumors in a given
patient and even within normal liver tissue. Because of
difﬁculties employing this methodology, alternative
activity determinants have been developed, which are
predominantly used in clinical practice and accepted as
viable surrogates.64
Resin 90Y microsphere activity calculation and
delivery techniques
Originally, the empiric method was used to calculate
treatment activity, which relied on the percentage of liver
involvement by tumor alone as the determinant of activ-
ity. This was abandoned as it became obvious that it did
not account for differences in liver volume amongst
individuals. Subsequently, the BSA method was instituted
and continues to be the principal method of activity
determination for resin microspheres.64 The calculated
activity using the BSA method uses the following
formula:
Prescribed Activity ðGBqÞZ BSA 0:2
þ Volume Tumor=ðVolume Tumor þ Volume LiverÞ
The BSA correlates well with liver volume except at
extremes of height and weight and in those instances
where the liver is markedly enlarged by tumor.65
For a bilobar (or segmental) treatment, the calculated
activity for the whole liver is multiplied by the percentage
by volume of the lobe (or segment) treated. For example,
in a 5’8”, 170-pound patient (BSA Z 1.9 m2) with 20%
liver involvement, the activity for the entire liver would
be:
Prescribed Activity for Entire LiverZ 1:9 0:2
þ 0:2Z 1:9GBq
With right and left lobe volumes being 60% and 40%
of the total liver volume, respectively, the activities for
each lobe are:
Right LobeZ 1:9  :6Z 1:14GBq
Left LobeZ 1:9  :4Z 0:76GBq
The BSA model is widely used in clinical practice as
well as in multiple studies including completed and
ongoing randomized controlled trials (Randomized PhaseIII Trial Comparing First-Line mFOLFOX6 (Plus or
Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus
Bevacizumab) Plus Selective Internal Radiation Therapy
in Patients With Metastatic Colorectal Cancer [SIR-
FLOX], FOLFOX6m Plus SIR-Spheres Microspheres vs
FOLFOX6m Alone in Patients With Liver Mets From
Primary Colorectal Cancer [FOXFIRE], FOXFIRE
Global). This methodology assumes even distribution of
tumor throughout the liver and does not account for dif-
ferences in tumor volume within treated lobes (or seg-
ments). To account for differences in tumor involvement
in treatment regions, the following equation is recom-
mended to ascertain the desired activity for a treatment
region (L)42:
ActivityL ðGBqÞZ

BSA 0:2þ Tumor volume
Treated lobar volume

 Treated lobar volume
Total liver volume
To assist in calculating prescribed activity, the Sirtex
Medical Activity Calculator was developed. This calcu-
lator allows for determination of activity to be adminis-
tered to a known liver volume containing a known
volume of tumor. It also automatically reduces the activity
if a lung dose of 25 Gy or greater is calculated using the
formula66:
Dose to Lung ðGyÞZActivity ðGBqÞ  50
 Lung Shunt ðLSÞ=Weight of Lung ðkgÞ
The Sirtex Medical Activity Calculator also allows for
activity reductions for those patients with risk factors for
the development of REILD including underlying liver
disease (cirrhosis), small livers or small tumor burdens,
and history of systemic chemotherapy. It is recommended
that these patients receive no more than 0.8 GBq per liter
of targeted liver.67
Resin 90Y microspheres administration
After the activity has been drawn into the supplied V
vial, it is placed within a Lucite box and the Delivery Set
containing needles and tubing properly ﬂushed and con-
nected to the V vial (see instructions for use). The
authorized user then agitates the microspheres with D5W,
delivering aliquots of activity through the tubing toward
the microcatheter. The interventional radiologist then
ﬂushes the microspheres through the delivery micro-
catheter with a D5W/contrast mixture (typically 50/50,
but up to the user’s discretion). The delivery of micro-
spheres occurs during real-time ﬂuoroscopic evaluation to
ensure that ﬂow is maintained within the vessel and that
the catheter remains in satisfactory position throughout
the delivery. When the V vial appears clear, the
Advances in Radiation Oncology: OctobereDecember 2016 Yttrium-90 radioembolization: History and current use 359authorized user pushes the remaining ﬂuid from the V vial
using an air-ﬁlled syringe.42Glass 90Y microsphere activity calculation and
delivery techniques
TheraSphere activity calculation is based on a
2-compartment partition model consisting of the lung and
the liver and assumes uniform distribution of micro-
spheres throughout the liver compartment. The percentage
of liver replaced by tumor does not factor into the activity
determination.40,64
The activity to be administered is calculated after a
desired dose to the liver has been chosen factoring in the
lung shunt calculated from the technetium 99-labeled
macroaggregated albumin study49Activity ðGBqÞZDesired Dose ðGyÞ  Mass of Targeted Liver ðkgÞ
50 ð1Lung Shunt FractionÞA dose of 100 to 140 Gy to the liver compartment is
typically chosen to determine activity to be administered
with lower doses chosen in patients with underlying liver
disease from any cause.
Recently the TheraSphere interactive dose ordering
calculator was developed to aid users in determining
activity to be delivered based on desired dose and timing
of administration.68Glass 90Y microspheres administration
TheraSphere microspheres are supplied in 0.6 mL
of sterile, pyrogen-free water contained in a 1.0 mL
V-bottom vial secured within a clear Lucite vial shield.
The vial is placed within a reusable Lucite delivery
box. A 2-needle plunger system connected to the
tubing assembly is inserted into the TheraSphere vial and
connection made to the microcatheter. A 20-mL syringe is
ﬁlled from the saline source and then injected into the
TheraSphere containing vial at a constant rate of 20 mL
per minute at a pressure not to exceed 30 psi. This high-
pressure, bolus technique is required due to the high
speciﬁc gravity of the microspheres, which will not be
properly agitated and delivered otherwise. This should be
repeated approximately 3 times to ensure thorough de-
livery of the activity.49 At no time during the adminis-
tration is it possible to inject contrast to evaluate for
changes in ﬂow within the hepatic artery.44,69
At the end of an administration using either SIR-
Spheres or TheraSphere, all of the disposable tubing andcatheters are placed in a container, which will be stored
until there has been adequate decay. Patients typically
have a posttreatment bremsstrahlung scan to localize the
delivered activity.64
Current clinical practice
A thorough discussion of the current practice of
hepatic radioembolization as it relates to clinical
outcomes, results of clinical trials to date, and the
status of ongoing randomized controlled trials is
beyond the scope of this manuscript. It is important to
note that no prospective randomized controlled
study has been performed to date comparing outcomes
between patients treated with glass or resin
microspheres.Appropriate patient selection is paramount to ensuring
minimal adverse events and maximum beneﬁcial outcome.
Bilirubin level is 1 of the most important parameters for
assessing appropriateness of radioembolization.64 Great
caution should be taken in treating patients with bilirubin
levels of 2.0 or greater; however, it may be safe in those
instances where minimal normal hepatic parenchyma is
included in the targeted volume such as segmental treat-
ments. Some reports indicate that a bilirubin level <1.2 is
associated with improved survival following radio-
embolization.70 Eastern Cooperative Oncology Group
status 2, minimal or stable extrahepatic disease, albumin
level >3.0 g/dL, and excessive tumor burden with limited
hepatic reserve are additional important indicators of
tolerability of the procedure. Regular assessment of these
parameters both before and following radioembolization is
recommended.68,69 Eastern Cooperative Oncology Group
status 2, minimal or stable extrahepatic disease, albumin
level >3.0 g/dL, and excessive tumor burden with limited
hepatic reserve are additional important indicators of
tolerability of the procedure. Regular assessment of these
parameters both before and following radioembolization is
recommended.71,72
Although the FDA-approved indication for SIR-
Spheres is for unresectable hepatic malignancies from
primary colorectal cancer and the HDE indication for
TheraSphere is for unresectable HCC,40,49 both devices
have been used to treat hepatic metastases from other
primary tumor types, including intrahepatic chol-
angiocarcinoma, neuroendocrine, breast, melanoma, renal
cell, lung, and pancreatic neoplasms.73-82
Table 2 Current randomized clinical trials of 90Y microspheres for primary or secondary liver tumors
Trial Location Intervention arms Primary endpoint n
mCRC (ﬁrst line)
SIRFLOX85 Global FOLFOX  bevacizumab
FOLFOX  bevacizumab
þ SIR-Spheres
PFS 530
FOXFIRE86 UK FOLFOX  biological agent
FOLFOX  biological agent
þ SIR-Spheres
OS 320
FOXFIRE Global95 Global FOLFOX  bevacizumab
FOLFOX  bevacizumab
þ SIR-Spheres
OS 200
mCRC (ﬁrst line after PR/SD following 3-6 months of induction chemotherapy)
SIR-step96 Belgium 5FU/LV  biological agent
5FU/LV  biological agent
þ SIR-Spheres
TTP 162
mCRC (second line)
EPOCH87 Global Standard of care chemotherapy
Standard of care chemotherapy
þ TheraSphere
PFS 340
HCC
SIRveNIB90 Global Sorafenib
SIRT with SIR-Spheres
OS 360
SARAH92 France Sorafenib
SIRT with SIR-Spheres
OS 496
SORAMIC91 Germany RFA  Sorafenib
Sorafenib  SIRT with
SIR-Spheres
TTR/OS 665
STOP-HCC88 Global Sorafenib
Sorafenib þ SIRT with
TheraSphere
OS 390
DOSISPHERES-0197 France Standard dosimetry SIRT
with TheraSphere
Optimized dosimetry SIRT
with TheraSphere
ORR 210
PREMIERE98 US TACE
SIRT with TheraSphere
TTP 124
TRACE99 Belgium TACE-DEB
SIRT with TheraSphere
TTP 140
HCC with PVT
YES-P89 Global Sorafenib
SIRT with TheraSphere
OS 328
ICC
NCT01798147100 Germany TACE-DEB
SIRT with SIR-Spheres
PFS 24
DEB, drug-eluting beads; FOLFOX, leucovorin þ ﬂuorouracil þ oxaliplatin; 5FU, ﬂuorouracil; HCC, hepatocellular carcinoma; ICC, intrahepatic
cholangiocarcinoma; LV, leucovorin; mCRC, metastatic colorectal cancer; PVT, portal vein thrombosis; RFA; radiofrequency ablation; SIRT,
selective internal radiation therapy; TACE, transarterial chemoembolization; TTR, time to recurrence.
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After 2 randomized trials demonstrated the safety and
promising efﬁcacy of SIRT in conjunctionwith oxaliplatin-
and ﬂuoropyrimidine-based chemotherapy regimens in
patientswithmCRC,83,84 randomized controlled trialswere
initiated to determine if radioembolization conferred added
beneﬁt when administered with FOLFOX or 5FU -Leucovorin - Oxaliplatin in the ﬁrst line. The recently re-
ported SIRFLOXTrial compared patients treated in the ﬁrst
line who received FOLFOX6 bevacizumab alone or with
radioembolization using 90Y resin microspheres. Although
there was no statistical difference in overall progression,
patients receiving radioembolization experienced a 7.9-
month longer median progression-free survival in the
liver than patients receiving standard therapy (PZ .002).85
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Global trials (also evaluating 90Y-resin SIRT plus FOL-
FOX), will be combined with the SIRFLOX data with a
primary outcome of improved overall survival.85,86
A second-line trial of 90Y glass microspheres in mCRC
patients with safety and efﬁcacy endpoints is also under
way. In this trial, patients will receive second-line
chemotherapy with or without radioembolization.87
Several randomized controlled trials evaluating radio-
embolization for HCC are ongoing including studies of
glass (STOP e HCC: Efﬁcacy Evaluation of TheraSphere
in Patients With Inoperable Liver Cancer, YES-P: Treat
Inoperable Liver Cancer With Blockage of the Portal
Vein) and resin (SIRveNIB: Study to Compare Selective
Internal Radiation Therapy [SIRT] Versus Sorafenib in
Locally Advanced Hepatocellular Carcinoma, SARAH:
SorAfenib Versus Radioembolization in Advanced
Hepatocellular Carcinoma, SORAMIC: Sorafenib and
Micro-Therapy Guided by Primovist Enhanced MRI in
Patients with Inoperable Liver Cancer) 90Y microspheres
(Table 2).88-92 Additional prospective studies are being
conducted with SIRT treatment for patients with meta-
static uveal melanoma, breast cancer, and renal cell car-
cinoma as well.93,94Choice of use of the two devices
As previously mentioned, there has been no random-
ized control trial performed to determine which of the
commercially available 90Y-labeled microspheres is clin-
ically superior. Deciding which device should be used is
an institutional choice and depends on the training of the
treating physicians, the local reimbursement policies, and
the ability to schedule a particular time in the interven-
tional radiology suite to deliver the therapy. Although
treating physicians can be trained to use either device, his
or her preference may reﬂect the fellowship training or
prior experience with the devices. State and local insur-
ance determinations of payment for these services will
also impact the choice because some states will not
reimburse for materials that are on a clinical trial, deﬁned
as an institutional review boardeapproved study. A
thorough understanding of the properties of the 2 devices
enables treating physicians to choose a product that best
suits their patients’ needs.Conclusion
Selective internal radiation therapy of hepatic malig-
nancies is a groundbreaking therapeutic modality that
requires the combined efforts of multiple medical disci-
plines to ensure the safe delivery of 90Y-labeled micro-
spheres. The development of this therapy followed
decades of clinical research involving tumor vascularityand microsphere development. The 2 commercially
available microspheres differ in many respects, but to
date, no randomized controlled trials have been conducted
to determine if these differences have clinical conse-
quences in their currently approved indications. As SIRT
expands into combination therapies and into patient
populations beyond HCC and mCRC, clinicians may be
able to take advantage of the individual attributes of resin
and glass 90Y microspheres to improve patient outcomes.Acknowledgments
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